Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and staging of endometrial cancer is the foundation for any successful treatment plan. For international patients seeking world‑class care, understanding each step helps reduce anxiety and ensures informed decisions. Each year, more than 380,000 women worldwide are diagnosed with this gynecologic malignancy, and early detection dramatically improves survival rates. This page explains the full pathway—from initial symptoms and clinical evaluation to advanced imaging, pathology, and the FIGO staging system—so you can anticipate what to expect at Liv Hospital.
Our multidisciplinary team combines expertise in gynecologic oncology, radiology, pathology and supportive care. Whether you are planning a comprehensive health‑check abroad or have been referred after a suspicious finding, the information below will guide you through the process, clarify terminology, and highlight the state‑of‑the‑art technologies we employ.
By the end of this guide, you will understand which tests are performed, how results are interpreted, and how the staging outcome shapes the personalized treatment roadmap at Liv Hospital.
Endometrial cancer originates in the lining (endometrium) of the uterus and is the most common gynecologic cancer in high‑income countries. While the exact cause remains multifactorial, several risk factors have been identified:
Typical early symptoms include abnormal uterine bleeding, especially post‑menopausal spotting, and pelvic pain. Recognizing these signs promptly leads to earlier diagnosis, which directly influences the stage at presentation. At Liv Hospital, a detailed medical history and physical examination are the first steps, allowing clinicians to assess symptom patterns, risk profile, and any prior imaging.
In addition to clinical assessment, blood tests such as a complete blood count and metabolic panel help evaluate overall health and readiness for potential surgery or systemic therapy. Understanding your personal risk factors equips you to engage actively with the care team throughout the staging process.
Accurate diagnosis requires a combination of minimally invasive procedures and laboratory analyses. The most common sequence includes:
At Liv Hospital, the endometrial biopsy is performed by a gynecologic oncologist in a comfortable outpatient setting. The sample is sent to a JCI‑accredited pathology lab, where it undergoes routine H&E staining and, when indicated, immunohistochemical profiling to determine tumor subtype (e.g., endometrioid, serous, clear cell). These results are essential for the subsequent staging work‑up.
When initial tests suggest malignancy, the team promptly schedules imaging studies to assess disease spread, ensuring a seamless transition from diagnosis to staging.
Imaging provides the anatomical roadmap needed to assign a precise stage. The choice of modality depends on tumor size, suspected spread, and patient factors. The primary imaging tools include:
Our radiology department utilizes a 3‑Tesla MRI scanner with dedicated pelvic coils, delivering high‑resolution images that differentiate between superficial and deep myometrial infiltration. The radiologist provides a structured report highlighting:
All imaging is reviewed in a multidisciplinary tumor board, where surgeons, oncologists, radiologists and pathologists discuss each case. This collaborative approach ensures that the imaging findings are accurately integrated into the final staging classification.
Pathology not only confirms cancer but also determines its grade, which reflects how much tumor cells differ from normal endometrial tissue. Grading is a key predictor of aggressiveness and influences treatment intensity. The most widely used system categorizes tumors into:
In addition to grade, the pathology report includes:
Our pathologists employ both conventional microscopy and molecular testing (e.g., POLE mutation, mismatch repair deficiency) when indicated. These molecular insights are increasingly incorporated into personalized treatment pathways, especially for patients who may benefit from immunotherapy.
The final pathology report, combined with imaging, completes the diagnosis and staging workflow, allowing the team to formulate a stage‑specific management plan.
Liv Hospital’s tumor board cross‑references imaging, pathology, and molecular data to assign the most accurate FIGO stage. This precision enables the selection of minimally invasive surgery when appropriate, or the integration of cutting‑edge systemic options such as immunotherapy for advanced disease.
Once the stage is established, a personalized treatment plan is crafted. The core team includes a gynecologic oncologist, medical oncologist, radiation oncologist, radiologist, pathologist, and a dedicated patient navigator who assists international visitors with logistics.
Key steps in the planning phase are:
Our facility offers state‑of‑the‑art robotic platforms, which reduce hospital stay and accelerate recovery. For patients requiring chemotherapy, we have an on‑site pharmacy that prepares individualized regimens, including immunotherapy agents when indicated by molecular profiling.
Throughout the entire pathway, the international patient services team arranges airport transfers, accommodation near the hospital, and translation services, ensuring that patients can focus solely on their health.
Liv Hospital is a JCI‑accredited, internationally recognized center that blends cutting‑edge technology with compassionate, multilingual care. Our gynecologic oncology unit follows evidence‑based protocols, and our radiology and pathology departments are equipped with the latest imaging and molecular diagnostics. International patients benefit from a 360‑degree support system that handles appointments, visa assistance, transportation, interpreter services, and comfortable lodging options—all coordinated by a dedicated patient liaison.
Ready to take the next step in your endometrial cancer journey? Contact Liv Hospital today to schedule a personalized consultation, and let our expert team guide you toward the most effective, tailored treatment plan.
Send us all your questions or requests, and our expert team will assist you.
Endometrial cancer typically presents with abnormal uterine bleeding, which may appear as unexpected spotting after menopause or irregular periods in pre‑menopausal women. Some patients also report pelvic or lower abdominal pain, a feeling of pressure, or a change in urinary habits if the tumor presses on nearby structures. Recognizing these symptoms early prompts timely evaluation with ultrasound and biopsy, which can lead to earlier diagnosis and a better prognosis.
The diagnostic pathway starts with a transvaginal ultrasound to measure endometrial thickness; a thickness greater than 5 mm in post‑menopausal women raises suspicion. If abnormal, an endometrial biopsy is performed to obtain tissue for histopathology, confirming malignancy. In cases where the biopsy is inconclusive, hysteroscopy allows direct visualization and targeted sampling of focal lesions. Blood tests for tumor markers such as CA‑125 and HE4 may be ordered to establish a baseline for future monitoring, especially in advanced disease.
A high‑resolution 3‑Tesla MRI with pelvic coils provides detailed images that differentiate superficial from deep myometrial infiltration. It accurately measures the percentage of myometrial invasion (<50 % = Stage IA, ≥50 % = Stage IB) and detects cervical stromal involvement, which defines Stage II disease. MRI also evaluates adjacent structures and can identify suspicious lymph nodes, guiding surgical planning and the need for adjuvant therapy.
The International Federation of Gynecology and Obstetrics (FIGO) staging groups endometrial cancer as follows: Stage I – tumor limited to the uterus (IA ≤50 % myometrial invasion, IB >50 %); Stage II – cervical stromal invasion without extra‑uterine spread; Stage III – spread to adnexa, vagina, or pelvic/para‑aortic lymph nodes; Stage IV – invasion of bladder or bowel mucosa (IVA) or distant metastasis (IVB). Accurate FIGO staging integrates imaging, pathology, and molecular data, and directly influences the choice of surgery, radiotherapy, chemotherapy, or targeted therapy.
Beyond routine histology, Liv Hospital’s pathology lab conducts molecular assays when indicated. POLE exonuclease domain mutations are associated with excellent prognosis and may spare patients from aggressive adjuvant therapy. MMR deficiency or microsatellite instability identifies tumors that could respond to immune checkpoint inhibitors. These molecular insights are incorporated into personalized treatment algorithms, especially for patients with high‑risk or recurrent disease.
BlogCancerFeb 19, 2026Patients often ask if they’ll be asleep during polyp removal. It depends on the polyp’s type an...
BlogCancerFeb 18, 2026Gynecological malignancies are cancers that affect the female reproductive system. They need accurate ICD-1...
BlogCancerFeb 18, 2026Diagnosis code C57.9 is a key ICD-10 code. It classifies malignant neoplasms of unspecified female genital ...
BlogCancerNov 03, 2025The Canadian Cancer Society says most women with uterine cancer get surgery. The surgery type depends on th...
BlogCancerNov 03, 2025Having a total hysterectomy is a big decision that affects a woman’s health. One worry is the chance ...
BlogCancerNov 03, 2025Many women feel anxious about medical imaging procedures. A transvaginal ultrasound is a tool used to see i...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
